The case for a medicare drug coverage benefit: a critical review of the empirical evidence.
about
Pharmaceutical policies: effects of cap and co-payment on rational use of medicinesPharmaceutical policies: effects of cap and co-payment on rational drug useThe effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysisUniversal prescription drug coverage in Canada: Long-promised yet undeliveredSystematic review on quality control for drug management programs: is quality reported in the literature?Registration for public drug benefits across areas of differing ethnic composition in British Columbia, Canada.Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.Persistent medication affordability problems among disabled Medicare beneficiaries after Part D, 2006-2011Is cost-related non-collection of prescriptions associated with a reduction in health? Findings from a large-scale longitudinal study of New Zealand adultsRace/ethnicity and nonadherence to prescription medications among seniors: results of a national studyImplementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions.What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.Coping with prescription drug cost sharing: knowledge, adherence, and financial burdenCost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study.Cost-related nonadherence to prescribed medicines among older Canadians in 2014: a cross-sectional analysis of a telephone survey.Medicare Part D coverage gap: race, gender, and cost-related medication nonadherence.Medicare prescription coverage and congressional gridlock.Exploring the demand for a voluntary Medicare prescription drug benefit.Reference drug pricingThe price elasticity of demand for pharmaceuticals amongst high-income older Australians: a natural experiment
P2860
Q24188009-640B3FBF-1FFA-4B7C-8A94-BB3177418534Q24242490-282EF34F-8403-48D1-B531-8659A989C933Q26829072-11F81A5B-0109-4B05-B1C3-BE9D41766829Q28069734-425C0263-31B7-4F89-86E5-C813E57038C3Q33412577-E062741D-C40D-4737-90D2-CB4A9404CF76Q33610837-25E04726-C109-4B47-B4F9-9434C79DD194Q35747442-AD63CDD2-3595-4E3E-9B29-6D13AA0BFAE1Q35963348-F4736149-ECF7-48E2-BFA9-314D89F3B97EQ36302740-954B8C47-CDED-4DB4-87AD-E7162C8AC7D2Q36416879-56A5B911-ABF5-4A9B-825E-463992CE8B20Q36666594-B2081EE7-707F-4C79-B5E3-1059B0228F2CQ36699426-F8C124F3-F0C1-48E6-9CCC-93667C212B5BQ36741639-947E0A78-6846-44B5-A677-B3F13C774ACEQ37194705-B8ED2BB5-9711-44B9-A43B-1A701DC54E61Q37609415-D33D2C50-05A7-4849-957F-AE12AC8A88CBQ37735873-8ADFA2BD-D94F-40D2-A90C-9C80BDD13A7BQ37735874-20E74264-2132-40B0-8C76-CC0DBCCEFCBDQ38977081-84C7239D-8BA9-489C-9320-5717FE75ACD4Q42346872-1C991A05-5CDF-48D9-8B70-315CEDF93CC0Q42565606-97DCAD3E-1E42-499A-9985-7D4DE2CF39DBQ42761712-2E7F42E3-CBEA-4C77-98A4-95C673FCC306Q58154706-E8BA4A77-7028-44D3-9325-3DC98CD7DB3D
P2860
The case for a medicare drug coverage benefit: a critical review of the empirical evidence.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The case for a medicare drug c ...... iew of the empirical evidence.
@ast
The case for a medicare drug c ...... iew of the empirical evidence.
@en
The case for a medicare drug c ...... iew of the empirical evidence.
@nl
type
label
The case for a medicare drug c ...... iew of the empirical evidence.
@ast
The case for a medicare drug c ...... iew of the empirical evidence.
@en
The case for a medicare drug c ...... iew of the empirical evidence.
@nl
prefLabel
The case for a medicare drug c ...... iew of the empirical evidence.
@ast
The case for a medicare drug c ...... iew of the empirical evidence.
@en
The case for a medicare drug c ...... iew of the empirical evidence.
@nl
P2093
P1476
The case for a medicare drug c ...... iew of the empirical evidence.
@en
P2093
Ross-Degnan D
Soumerai SB
P356
10.1146/ANNUREV.PUBLHEALTH.22.1.49
P577
2001-01-01T00:00:00Z